Dongwoon Anatech FY 2025 Annual ReportBeta
Dongwoon Anatech annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 19, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Dongwoon Anatech FY 2025 Annual Report Analysis
Business Overview
- • System semiconductor fabless with revenue from OIS IC, HAPTIC IC, BLDC, VCSEL IC, and new healthcare diagnostic segment in FY2025
- • AI-based saliva glucose diagnostic device D-SaLife prototype developed, mass production planned for 2026
Management Discussion & Analysis
- • Revenue KRW 127.63B (-7.7% YoY), operating profit KRW 2.42B (-86.1%), net income KRW 1.02B (-95.8%) for fiscal 2025
- • Decreased operating profit driven by higher personnel expenses and R&D costs
Risk Factors
- • KRW 40.7B total debt at FY2025-end, up from KRW 27.5B prior year, debt ratio 58.8% vs 38.6%
- • FX exposure to USD and JPY foreign exchange risk with matching currency inflow/outflow policy to minimize risk
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding